Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Brain Res Bull ; 187: 162-168, 2022 09.
Artículo en Inglés | MEDLINE | ID: mdl-35781030

RESUMEN

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder with a higher susceptibility to occur in men. Studies suggest that this susceptibility is related to the hormonal differences observed between men and women, being a risk factor for PD. In addition, testosterone supplementation has shown controversial results in animal models of PD and parkinsonian patients. This study evaluated the effect of chronic administration of testosterone propionate (TP) on motor behavior and neurochemical parameters in the reserpine-induced rat model of parkinsonism. Male Wistar rats received 15 injections of reserpine (RES - 0.1 mg/kg) every other day and were concomitantly treated with different doses (0.1, 1.0, or 5.0 mg/kg) of daily TP for 30 days. The rats were euthanized 48 h after the 15th injection of RES or vehicle. Brains were removed and subjected to Tyrosine hydroxylase (TH) immunohistochemistry. TP at 1.0 mg/kg reduced the damages caused by reserpine in the vacuous chewing and tong protrusion behaviors and prevented dopaminergic damage in the SNpc, VTA, and Striatum. TP at 5.0 mg/kg reduced the damages caused by reserpine in the catalepsy and tong protrusion behaviors, prevented the weight loss, and prevented dopaminergic damage in the VTA. Our results suggest that chronic administration of TP has a protective effect in a rat model of parkinsonism, improving motor alterations and dopamine depletion induced by RES.


Asunto(s)
Enfermedad de Parkinson , Trastornos Parkinsonianos , Propionato de Testosterona , Animales , Modelos Animales de Enfermedad , Dopamina/farmacología , Femenino , Humanos , Masculino , Actividad Motora , Trastornos Parkinsonianos/inducido químicamente , Ratas , Ratas Wistar , Reserpina/farmacología , Tirosina 3-Monooxigenasa
2.
Nitric Oxide ; 124: 24-31, 2022 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-35533947

RESUMEN

Fear is an emotional reaction that arises in dangerous situations, inducing the adaptation to an existing condition. This behavior was conserved in all vertebrates throughout evolution and is observed in mammals, birds, fish, amphibians, and reptiles. The neurocircuitry of fear involves areas of the limbic system, cortical regions, midbrain, and brainstem. These areas communicate with each other so that there is an expression of fear and memory formation to deal with the same situation at another time. The effect of nitric oxide (NO) on fear modulation has been explored. NO is a gaseous compound that easily diffuses through the cell membrane and is produced through the oxidation reaction of l-Arginine to l-citrulline catalyzed by nitric oxide synthase (NOS). Activating the intracellular NO receptor (soluble guanylyl cyclase enzyme - sGC) triggers an enzymatic cascade that can culminate in plastic events in the neuron. NOS inhibitors induce anxiolytic-like responses in fear modulation, whereas NO donors promote fear- and anxiety-like behaviors. This review describes the neurobiology of fear in mammals and non-mammals, how NO is produced in the central nervous system, and how NO acts in fear-like behavior.


Asunto(s)
Guanilato Ciclasa , Óxido Nítrico , Animales , Miedo , Guanilato Ciclasa/metabolismo , Mamíferos/metabolismo , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa , Guanilil Ciclasa Soluble
3.
Brain Res Bull ; 181: 55-64, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-35041849

RESUMEN

Believed to cause damage to the nervous system and possibly being associated with neurodegenerative diseases, deltamethrin (DM) is a type II pyrethroid used in pest control, public health, home environment, and vector control. The objective of this study was to evaluate the motor, cognitive and emotional changes associated with dopaminergic and BDNF imbalance after DM exposure in rats. Sixty Wistar rats (9-10 months-old) were used, under Ethics Committee on Animal Research license (ID 19/2017). The animals were randomly divided into four groups: control (CTL, 0.9% saline), DM2 (2 mg DM in 1.6 mL 0.9% saline), DM4 (4 mg of DM in 1.6 mL of 0.9% saline), and DM8 (8 mg of DM in 1.6 mL of 0.9% saline). DM groups were submitted to 9 or 15 inhalations, one every 48 h. Half of the animals from each group were randomly selected and perfused 24 h after the 9th or 15th inhalation. Throughout the experiment, the animal's behavior were evaluated using catalepsy test, open field, hole-board test, Modified Elevated Plus Maze, and social interaction. At the end of the experiments, the rats were perfused transcardially and their brains were processed for Tyrosine Hydroxylase (TH) and Brain derived neurotrophic factor (BDNF) immunohistochemistries. The animals submitted to 9 inhalations of DM showed a reduction in immunoreactivity for TH in the Substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), and dorsal striatum (DS) areas, and an increase in BDNF in the DS and CA1, CA3 and dentate gyrus (DG) hippocampal areas. Conversely, the animals submitted to 15 inhalations of DM showed immunoreactivity reduced for TH in the SNpc and VTA, and an increase in BDNF in the hippocampal areas (CA3 and DG). Our results indicate that the DM inhalation at different periods induce motor and cognitive impairments in rats. Such alterations were accompanied by dopaminergic system damage and a possible dysfunction on synaptic plasticity.


Asunto(s)
Ansiedad/inducido químicamente , Factor Neurotrófico Derivado del Encéfalo/efectos de los fármacos , Encéfalo/efectos de los fármacos , Disfunción Cognitiva/inducido químicamente , Insecticidas/farmacología , Trastornos de la Memoria/inducido químicamente , Actividad Motora/efectos de los fármacos , Síndromes de Neurotoxicidad/etiología , Nitrilos/farmacología , Piretrinas/farmacología , Tirosina 3-Monooxigenasa/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Dopamina/metabolismo , Exposición por Inhalación , Insecticidas/administración & dosificación , Nitrilos/administración & dosificación , Piretrinas/administración & dosificación , Distribución Aleatoria , Ratas , Ratas Wistar , Conducta Social
4.
Brain Res Bull ; 171: 1-9, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33675933

RESUMEN

Nociception alterations are frequent non-motor symptoms of the prodromal phase of Parkinson's disease (PD). The period for the onset of symptoms and the pathophysiological mechanisms underlying these alterations remain unclear. We investigated the course of nociception alterations in a progressive model of parkinsonism induced by reserpine (RES) in rats. Male Wistar rats (6-7 months) received 5 or 10 subcutaneous injections of RES (0.1 mg/kg) or vehicle daily for 20 days. Motor evaluation and nociceptive assessment were performed throughout the treatment. At the end of the treatment rats were euthanized, the brains removed and processed for immunohistochemical analysis (TH and c-Fos). The RES-treated rats exhibited an increased nociceptive response to mechanical and chemical stimulation in the electronic von Frey and formalin tests, respectively. Moreover, these alterations preceded the motor impairment observed in the catalepsy test. In addition, the RES treatment reduced the TH-immunoreactivity in the ventral tegmental area (VTA) and increased the c-Fos expression in the ventral-lateral periaqueductal gray (vlPAG), rostral ventral medulla (RVM) and dorsal raphe nucleus (DRN) after noxious stimuli induced by formalin. Taken together, our results reinforce that nociceptive changes are one of the early signs of PD and monoamine depletion in basal ganglia can be involved in the abnormal processing of nociceptive information in PD.


Asunto(s)
Núcleo Dorsal del Rafe/metabolismo , Actividad Motora/fisiología , Nocicepción/fisiología , Enfermedad de Parkinson Secundaria/fisiopatología , Sustancia Gris Periacueductal/metabolismo , Área Tegmental Ventral/metabolismo , Animales , Modelos Animales de Enfermedad , Núcleo Dorsal del Rafe/fisiopatología , Masculino , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/metabolismo , Sustancia Gris Periacueductal/fisiopatología , Proteínas Proto-Oncogénicas c-fos/metabolismo , Ratas , Ratas Wistar , Reserpina , Tirosina 3-Monooxigenasa/metabolismo , Área Tegmental Ventral/fisiopatología
5.
Behav Brain Res ; 393: 112806, 2020 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-32673706

RESUMEN

Environmental enrichment (EE) has been used to investigate behavioral changes and neuroplasticity in brain in normal and pathological conditions. Besides, the EE has been used to understand the neurobehavioral systems involved in learning experiences, visual inputs, defensive responses, social interactions and memory. However, the required exposure duration to remove aversive memories remains lacking. Therefore, the purpose of the present study was to investigate the time-course effect of EE exposure on the extinction of aversive memory. Young adult male Wistar rats were exposed to two different EE protocols: short-term environmental enrichment (EE2 - animal kept under enriched conditions for two weeks) and long-term environmental enrichment (EE4 - animal kept under enriched conditions for four weeks). The contextual fear conditioning test was used to assess aversive memory. The both EE protocols provide changes in Zif-268 immunoreactivity in mesocorticolimbic areas such as CA1 and central amygdala; however, only short-term EE reduces the ZIF-268 immunoreactivity in VTA. Besides, both EE protocols also provide an increase in TH immunoreactivity in VTA and nucleus accumbens, but only the short-term EE modifies the TH immunoreactivity in CA1 and infralimbic region of the prefrontal cortex. The time-course effect of EE interferes differently on the extinction of aversive memory, being two weeks of exposure with EE sufficient to cause improvement in coping during aversive situations, favoring the extinction of conditioned fear memory.


Asunto(s)
Ambiente , Extinción Psicológica/fisiología , Memoria/fisiología , Animales , Región CA1 Hipocampal/fisiología , Núcleo Amigdalino Central/fisiología , Proteína 1 de la Respuesta de Crecimiento Precoz/análisis , Masculino , Núcleo Accumbens/fisiología , Ratas Wistar , Área Tegmental Ventral/fisiología
6.
Behav Brain Res ; 363: 23-29, 2019 05 02.
Artículo en Inglés | MEDLINE | ID: mdl-30690108

RESUMEN

Parkinson's disease (PD) exhibits sexual differences in susceptibility and pathogenesis in humans, with a high incidence in men and a high severity of motor symptoms in male rodents. Furthermore, studies showed that the administration of low dose of reserpine (RES) induces a progressive appearance of motor alterations similar with parkinsonism in male rodents. Here, we investigated sex differences in motor deficits and tyrosine hydroxylase (TH) immunoreactivity induced by a progressive model of parkinsonism. Gonadally intact male and female Wistar rats and ovariectomized female rats received 15 subcutaneous injections (s.c.) every other day of 0.1 mg/kg of RES or vehicle. The repeated administration of low doses of RES (0.1 mg/kg) produces sexually dimorphic impairments on motor performance (catalepsy and open field test). Intact and ovariectomized females were more resistant to the deleterious effect of repeated administration of reserpine in the early, but this resistance in intact female disappears over time. However, intact females showed a reduction of the TH immunoreactivity in substantia nigra pars compacta, but not in ventral tegmental area and dorsal striatum. These results suggest a possible application of this model in the study of sexual dimorphism throughout the progression of PD.


Asunto(s)
Actividad Motora/efectos de los fármacos , Trastornos Parkinsonianos/patología , Factores Sexuales , Animales , Conducta Animal/efectos de los fármacos , Cuerpo Estriado/efectos de los fármacos , Modelos Animales de Enfermedad , Dopamina/metabolismo , Dopamina/fisiología , Femenino , Masculino , Enfermedad de Parkinson/patología , Trastornos Parkinsonianos/metabolismo , Ratas , Ratas Wistar , Reserpina/farmacología , Caracteres Sexuales , Sustancia Negra/efectos de los fármacos , Tirosina 3-Monooxigenasa/farmacología
7.
Brain Res Bull ; 142: 297-303, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-30118749

RESUMEN

Parkinson's disease (PD) is a neurodegenerative disease related to the dopaminergic system. The etiology is not fully understood, but it is known that PD is a multifactorial disease that involves genetic and environmental factors, including pesticides. One of these, Deltamethrin (DM), has been widely used for vector control in crops, farming, veterinary medicine and domestic pest control. The purpose of the present study was to investigate the effect of DM repeated administration on motor, cognitive and emotional behavior and dopaminergic parameters. Male Wistar rats received 3 intranasal (i.n.) injections of 100 µL (50 µL/nostril) of DM 0.5 µg/µl or Vehicle (saline solution 0.9%), one injection per week. We observed that DM caused memory (novel object recognition task) and emotion (contextual conditioned fear) alterations accompanied by reduction of TH immunoreactivity in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA), and increase of TH immunoreactivity in the dorsal striatum. Motor alterations (catalepsy and open field task) were not observed throughout treatment. These findings suggest a possible early disruption of the dopaminergic pathway caused by repeated DM exposure, similar to that observed in early stages of PD.


Asunto(s)
Emociones/efectos de los fármacos , Memoria/efectos de los fármacos , Nitrilos/efectos adversos , Plaguicidas/efectos adversos , Piretrinas/efectos adversos , Tirosina 3-Monooxigenasa/metabolismo , Administración Intranasal , Animales , Emociones/fisiología , Masculino , Memoria/fisiología , Trastornos de la Memoria/etiología , Trastornos de la Memoria/metabolismo , Trastornos de la Memoria/patología , Actividad Motora/efectos de los fármacos , Trastornos Parkinsonianos/etiología , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/patología , Porción Compacta de la Sustancia Negra/efectos de los fármacos , Porción Compacta de la Sustancia Negra/metabolismo , Porción Compacta de la Sustancia Negra/patología , Distribución Aleatoria , Ratas Wistar , Área Tegmental Ventral/efectos de los fármacos , Área Tegmental Ventral/metabolismo , Área Tegmental Ventral/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA